Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:57:42 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



Q:RNA - AVIDITY BIOSCIENCES INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
RNA - Q1.023.90·25.000.924.36+0.532.21,034.624,5357,63224.01  24.76  23.4927.66  4.82516:20:00Apr 2215 min RT 2¢

Recent Trades - Last 10 of 7632
Time ETExPriceChangeVolume
16:20:00Q24.360.53576
16:13:42Q24.360.5327
16:02:12Q24.360.53143
16:01:47Q24.360.531,163
16:01:26Q24.360.53496
16:01:08Q24.360.53600
16:01:06Q24.360.53164
16:01:02Q24.360.53359
16:00:03Q24.360.5379
16:00:02Q24.360.5319

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-22 16:05U:RNANews ReleaseAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-27 09:00U:RNANews ReleaseAvidity Biosciences to Participate in Upcoming Investor Conferences
2024-03-21 16:05U:RNANews ReleaseAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-04 07:00U:RNANews ReleaseAvidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR(TM) Trial
2024-02-29 12:00U:RNANews ReleaseAvidity Biosciences Honors Rare Disease Day(TM)
2024-02-29 07:00U:RNANews ReleaseAvidity Biosciences Announces Oversubscribed $400 Million Private Placement
2024-02-28 16:05U:RNANews ReleaseAvidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights
2024-02-27 09:00U:RNANews ReleaseAvidity Biosciences to Participate in Upcoming Investor Conferences
2024-02-21 16:05U:RNANews ReleaseAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-20 09:00U:RNANews ReleaseAvidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping
2024-02-15 17:00U:RNANews ReleaseAvidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE ¢ „ ¢ Trial in People Living with Myotonic Dystrophy Type 1 (DM1) at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
2024-01-22 16:05U:RNANews ReleaseAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-05 08:30U:RNANews ReleaseAvidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth
2023-12-21 16:05U:RNANews ReleaseAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-12-13 08:30U:RNANews ReleaseAvidity Biosciences Reports Positive Data Demonstrating AOC 1044 Delivers Unprecedented Concentrations of PMO in Muscle Following a Single Dose in Healthy Volunteers from Phase 1/2 EXPLORE44 ¢ „ ¢ Trial for Duchenne Muscular Dystrophy
2023-11-28 06:30U:RNANews ReleaseAvidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC ¢ „ ¢ Platform Technology
2023-11-21 16:05U:RNANews ReleaseAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-21 09:00U:RNANews ReleaseAvidity Biosciences to Participate in Upcoming Investor Conference
2023-11-08 16:05U:RNANews ReleaseAvidity Biosciences Reports Third Quarter 2023 Financial Results and Recent Highlights
2023-10-23 16:05U:RNANews ReleaseAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)